CStone Pharmaceuticals Co. Ltd.
http://www.cstonepharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CStone Pharmaceuticals Co. Ltd.
Blueprint RETreats As It Sells US Gavreto Rights To Rigel
After sales of the RET inhibitor have been commercially disappointing, Blueprint said it is selling US rights to the drug to Rigel for $15m up front and potentially more than $100m in milestones.
Asia Deal Watch: Argo Partners RNAi Programs With Novartis In Major Biobucks Pact
Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.
Chinese Domestic Alliances Focus On China-Only Rights As Confidence Grows
Confidence in growing in-house commercial capabilities has recently prompted several Chinese pharmas, including Simcere and 3SBio, to focus on obtaining domestic rights to novel drug assets developed by other China-based biotechs, rather than pursuing international deals.
Shanghai Eyes Commercial Insurance Push To Address Drug Firms’ Pricing Concerns
As Shanghai seeks to develop into an international biopharma hub, the local government is encouraging commercial medical insurers to cover more innovative drugs in their products. The policy aims to provide an alternative solution to dominant pricing by the national public payer, which often imposes deep discounts on novel drugs in exchange for reimbursement coverage.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice